Cargando…

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown. In this study, we found that Ibrutinib induced stronger cytotoxic effect on endothelial cells than Zanubruti...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jia, Liu, Zhuojun, Zhang, Jing, Chen, Xiaofang, Chen, Junge, Sui, Linlin, Yu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506105/
https://www.ncbi.nlm.nih.gov/pubmed/36145624
http://dx.doi.org/10.3390/pharmaceutics14091876
_version_ 1784796640014499840
author Liu, Jia
Liu, Zhuojun
Zhang, Jing
Chen, Xiaofang
Chen, Junge
Sui, Linlin
Yu, Jian
author_facet Liu, Jia
Liu, Zhuojun
Zhang, Jing
Chen, Xiaofang
Chen, Junge
Sui, Linlin
Yu, Jian
author_sort Liu, Jia
collection PubMed
description BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown. In this study, we found that Ibrutinib induced stronger cytotoxic effect on endothelial cells than Zanubrutinib, however, Acalabrutinib cytotoxicity was extremely weak. RNA-seq, followed by KEGG analysis and quantitative RT-PCR validation, was conducted to identify the differential apoptotic target genes of BTKis, leading to their distinct cytotoxic effects on endothelial cells, which showed that Ibrutinib and Zanubrutinib dramatically modulated the expression of critical apoptotic genes, GADD45B, FOS, and BCL2A1, among which FOS and GADD45B were upregulated more significantly by Ibrutinib than Zanubrutinib, however, Acalabrutinib downregulated BCL2A1 moderately and was not able to modulate the expression of FOS and GADD45B. Next, we performed in vitro angiogenesis assays and found that Ibrutinib was more able to induce endothelial dysfunction than Zanubrutinib via stimulating more BMP4 expression, however, Acalabrutinib had no such effect. Especially, the capacity of Ibrutinib to induce endothelial dysfunction can be antagonized by targeting BMP4. Accordingly, Ibrutinib, as an angiogenesis inhibitor, inhibited ovarian and breast cancer progression in vivo. Collectively, our findings addressed a novel molecular basis underlying Ibrutinib-induced endothelial cell dysfunction and suggested the potential application of Ibrutinib to treat angiogenesis-dependent cancers.
format Online
Article
Text
id pubmed-9506105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95061052022-09-24 Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner Liu, Jia Liu, Zhuojun Zhang, Jing Chen, Xiaofang Chen, Junge Sui, Linlin Yu, Jian Pharmaceutics Article BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown. In this study, we found that Ibrutinib induced stronger cytotoxic effect on endothelial cells than Zanubrutinib, however, Acalabrutinib cytotoxicity was extremely weak. RNA-seq, followed by KEGG analysis and quantitative RT-PCR validation, was conducted to identify the differential apoptotic target genes of BTKis, leading to their distinct cytotoxic effects on endothelial cells, which showed that Ibrutinib and Zanubrutinib dramatically modulated the expression of critical apoptotic genes, GADD45B, FOS, and BCL2A1, among which FOS and GADD45B were upregulated more significantly by Ibrutinib than Zanubrutinib, however, Acalabrutinib downregulated BCL2A1 moderately and was not able to modulate the expression of FOS and GADD45B. Next, we performed in vitro angiogenesis assays and found that Ibrutinib was more able to induce endothelial dysfunction than Zanubrutinib via stimulating more BMP4 expression, however, Acalabrutinib had no such effect. Especially, the capacity of Ibrutinib to induce endothelial dysfunction can be antagonized by targeting BMP4. Accordingly, Ibrutinib, as an angiogenesis inhibitor, inhibited ovarian and breast cancer progression in vivo. Collectively, our findings addressed a novel molecular basis underlying Ibrutinib-induced endothelial cell dysfunction and suggested the potential application of Ibrutinib to treat angiogenesis-dependent cancers. MDPI 2022-09-05 /pmc/articles/PMC9506105/ /pubmed/36145624 http://dx.doi.org/10.3390/pharmaceutics14091876 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Jia
Liu, Zhuojun
Zhang, Jing
Chen, Xiaofang
Chen, Junge
Sui, Linlin
Yu, Jian
Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
title Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
title_full Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
title_fullStr Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
title_full_unstemmed Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
title_short Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
title_sort ibrutinib inhibits angiogenesis and tumorigenesis in a btk-independent manner
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506105/
https://www.ncbi.nlm.nih.gov/pubmed/36145624
http://dx.doi.org/10.3390/pharmaceutics14091876
work_keys_str_mv AT liujia ibrutinibinhibitsangiogenesisandtumorigenesisinabtkindependentmanner
AT liuzhuojun ibrutinibinhibitsangiogenesisandtumorigenesisinabtkindependentmanner
AT zhangjing ibrutinibinhibitsangiogenesisandtumorigenesisinabtkindependentmanner
AT chenxiaofang ibrutinibinhibitsangiogenesisandtumorigenesisinabtkindependentmanner
AT chenjunge ibrutinibinhibitsangiogenesisandtumorigenesisinabtkindependentmanner
AT suilinlin ibrutinibinhibitsangiogenesisandtumorigenesisinabtkindependentmanner
AT yujian ibrutinibinhibitsangiogenesisandtumorigenesisinabtkindependentmanner